Evidence map›Paper›PMID 30043213›Full record

ArticleInflammopharmacology2018

Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease.

Dorota Sikorska, Zofia Orzechowska, Rafał Rutkowski, Anna Prymas, Marta Mrall-Wechta, Daria Bednarek-Hatlińska, Magdalena Roszak, Anna Surdacka, Włodzimierz Samborski, Janusz Witowski

Open access · hybridAbstract read
In one paragraph

Article in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Dorota SikorskaDepartment of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, 28-Czerwca 1956 Street 135/147, 61-545, Poznan, Poland. dorotasikorska@ump.edu.pl.ORCID http://orcid.org/0000-0001-7326-6916
Zofia OrzechowskaDepartment of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland.
Rafał RutkowskiDepartment of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland.
Anna PrymasDepartment of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, Poznan, Poland.
Marta Mrall-WechtaDepartment of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, Poznan, Poland.
Daria Bednarek-HatlińskaDepartment of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, Poznan, Poland.
Magdalena RoszakDepartment of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland.
Anna SurdackaDepartment of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, Poznan, Poland.
Włodzimierz SamborskiDepartment of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, 28-Czerwca 1956 Street 135/147, 61-545, Poznan, Poland.
Janusz WitowskiDepartment of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland.
Poznan University of Medical Sciences · PL

Funding

Poznan University of Medical Sciences 502-14-02230375-10572
6 · The paper itself

Abstract

introductionSaliva has been increasingly used as a diagnostic medium for disease detection and monitoring. The aim of this observational, prospective, pilot study was to investigate whether salivary concentrations of CRP and IL-6 correlate with those in serum and with the clinical course of a rheumatic disease. MATERIALS AND

methodsNineteen patients with rheumatic disease newly scheduled for anti-TNFα therapy were included. Patients received anti-TNFα treatment (adalimumab, certolizumab, golimumab or infliximab) as per standard protocols. CRP and IL-6 were measured with high-sensitivity immunoassays before and after 12 weeks of therapy, according to standard regimens. The data were analyzed with nonparametric statistics.

resultsConcentrations of CRP in saliva correlated significantly with those in serum (R = 0.62; p < 0.0001) and decreased markedly after successful response to treatment. In patients with a limited response to treatment salivary CRP levels increased. In contrast to CRP, the salivary concentrations of IL-6 did not change significantly over the course of therapy and they did not correlate with serum IL-6 concentrations. Salivary levels of neither CRP nor IL-6 corresponded to parameters of oral health and hygiene.

conclusionsSalivary CRP but not IL-6 could be of potential use for monitoring the rheumatic disease activity.

Indexed as

AdultC-Reactive ProteinFemaleHumansInterleukin-6MaleMiddle AgedRheumatic DiseasesSalivaTumor Necrosis Factor-alphaC-Reactive ProteinInterleukin-6Tumor Necrosis Factor-alphaBiologic therapyC-reactive proteinInterleukin-6Rheumatic diseaseSaliva

Identifiers

PMID30043213
PMCPMC6153921
OpenAlexW2883908810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.